GSK 1070806
Alternative Names: GSK-1070806Latest Information Update: 26 Jun 2025
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 18 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Crohn's disease; Delayed graft function; Inflammatory bowel diseases; Type 2 diabetes mellitus
Most Recent Events
- 26 Jun 2025 Discontinued - Phase-I for Atopic dermatitis (In adults, In the elderly) in Canada (IV)
- 26 Jun 2025 Discontinued - Phase-I for Atopic dermatitis (In the elderly, In adults) in USA (IV)
- 26 Jun 2025 Discontinued - Phase-I for Inflammatory bowel diseases (In volunteers) in United Kingdom (IV) (GSK pipeline, June 2024)